Comparative Pharmacology
Head-to-head clinical analysis: FYCOMPA versus ZONISAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FYCOMPA versus ZONISAMIDE.
FYCOMPA vs ZONISAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-competitive AMPA receptor antagonist; inhibits glutamate-mediated excitatory neurotransmission by selectively targeting AMPA receptors.
Anticonvulsant; blocks voltage-gated sodium channels and T-type calcium channels, reducing neuronal excitability and seizure propagation. Also weakly inhibits carbonic anhydrase.
Initial: 2 mg orally once daily; titrate weekly by 2 mg increments to maintenance dose of 4-12 mg once daily depending on seizure type and tolerability; maximum 12 mg once daily.
Oral, initial 100 mg daily, may increase by 100 mg every 2 weeks; maintenance 200-400 mg daily in 1-2 divided doses; maximum 600 mg daily.
None Documented
None Documented
Clinical Note
moderateZonisamide + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Zonisamide."
Clinical Note
moderateZonisamide + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Zonisamide."
Clinical Note
moderateZonisamide + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Zonisamide."
Clinical Note
moderateZonisamide + Fluconazole
Terminal elimination half-life is approximately 105 hours (range 80-120 hours) in patients with epilepsy; supports once-daily dosing.
Terminal half-life approximately 60-70 hours (range 50-80 hours) in adults; at steady state, half-life may be slightly longer. Clinical context: requires 2-3 weeks to achieve steady state.
Renal: approximately 30% as unchanged drug; fecal: approximately 70% (mostly as metabolites, minimal unchanged).
Renal: approximately 30% unchanged; remainder as glucuronide conjugate and reduced metabolite. Biliary/fecal: minimal (<5%).
Category C
Category C
Anticonvulsant
Anticonvulsant
"The metabolism of Fluconazole can be decreased when combined with Zonisamide."